KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Predicting Long-Term Engagement in mHealth Apps: Comparative Study of Engagement Indices. PMID 39250192 · J Med Internet Res · 2024-Sep-09 The record describes a randomized study of a mobile health app in cancer survivors but does not meet the core criteria: it is not a Phase III/IIIb or Phase II/III trial of a drug-containing intervention with a primary time-to-event clinical efficacy endpoint (OS, PFS, etc.). The engagement indices are not standard oncology efficacy endpoints.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. PMID 39094560 · Cancer Cell · 2024-Sep-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of fentanyl inhalant for the treatment of breakthrough cancer pain: a multicenter, randomized, double-blind, placebo-controlled trial. PMID 39244530 · BMC Palliat Care · 2024-Sep-07 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Thromboprophylaxis in oesophageal cancer patients-a study protocol for a randomised, controlled trial (TOP-RCT). PMID 39242497 · Trials · 2024-Sep-06 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Impact of a multimodal effort re-education programme on functionality, physical performance, and functional capacity in cancer patients with dyspnoea: a randomised experimental study. PMID 39237780 · Support Care Cancer · 2024-Sep-06 The study is a randomized controlled trial in cancer patients, but it is not a Phase III/IIIb or Phase II/III drug intervention trial. The intervention is an exercise re-education programme (non-drug). The primary endpoint is functionality (MRC dyspnoea scale), not a time-to-event efficacy endpoint (OS, PFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. PMID 39235326 · Oncologist · 2024-Sep-06 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
It is time to rethink randomized clinical trial approaches. PMID 38986514 · Oncologist · 2024-Sep-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of Perioperative Lidocaine on Neutrophil Extracellular Trapping and Serum Cytokines in Robot-Assisted Radical Prostatectomy: Randomized Controlled Study. PMID 39336493 · Medicina (Kaunas) · 2024-Sep-05 The study is a randomized controlled trial in oncology (prostate cancer) and reports original results. However, it is excluded because: (1) the intervention is perioperative lidocaine, which is not a systemic anticancer drug intervention as required; (2) the primary endpoint, biochemical recurrence (BCR), is not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) with reported Kaplan-Meier or hazard ratio analysis; (3) the trial phase is not specified as Phase III/IIIb or definitively established as such.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCL. PMID 38820500 · Blood · 2024-Sep-05 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dietary Counseling Outcomes in Patients with Lung Cancer in an Upper-Middle-Income Country: An Open-Label Randomized Controlled Trial. PMID 39274449 · J Clin Med · 2024-Sep-04 The study is an oncology RCT in human lung cancer patients with time-to-event endpoints (PFS, OS), but the intervention is dietary counseling (non-drug-only). The phase is not explicitly confirmed as Phase III/IIIb or Phase II/III. Therefore, it does not meet the criteria for a drug-containing intervention and definitive phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Omentum preservation versus complete omentectomy in gastrectomy for gastric cancer (OMEGA trial): study protocol for a randomized controlled trial. PMID 39232781 · Trials · 2024-Sep-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Protocol for a prospective multicenter randomized controlled trial to evaluate the efficacy of texture and color enhancement imaging (TXI) observation in the detection of colorectal lesions (deTXIon study). PMID 38762330 · Jpn J Clin Oncol · 2024-Sep-04 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Number of lymph nodes retrieved in patients with locally advanced rectal cancer after total neoadjuvant therapy: post-hoc analysis from the STELLAR trial. PMID 39382122 · BJS Open · 2024-Sep-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Calibrating Observational Health Record Data Against a Randomized Trial. PMID 39348118 · JAMA Netw Open · 2024-Sep-03 This is a retrospective cohort study using EHR data to emulate and calibrate against a known RCT (KEYNOTE-189), not an original report of a Phase III/IIIb or Phase II/III randomized trial with a drug intervention and a primary/key secondary time-to-event efficacy endpoint. The phase, randomization, drug intervention, endpoint, and original-report evidence are not established for this record.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Trifecta Outcomes After Use of 3-Dimensional Digital Models for Planning of Robotic Prostatectomy: A Secondary Analysis of a Randomized Clinical Trial. PMID 39283633 · JAMA Netw Open · 2024-Sep-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Phase II Study of Potentiation of Pembrolizumab with Binimetinib and Bevacizumab in Refractory Microsatellite-Stable Colorectal Cancer. PMID 38869830 · Clin Cancer Res · 2024-Sep-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
An Analysis of PIK3CA Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials. PMID 38837894 · Clin Cancer Res · 2024-Sep-03 The record describes a biomarker-correlative analysis of PIK3CA mutations pooled from four neoadjuvant trials. While the underlying trials are randomized and oncology-focused with drug interventions, this specific publication is a secondary analysis investigating predictive biomarkers for response (pCR) and exploratory survival, not a primary report of a definitive randomized trial's key efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Limited fasciectomy with versus without autologous adipose tissue grafting for treatment of Dupuytren's contracture (REMEDY): study protocol for a multicentre randomised controlled trial. PMID 39223657 · Trials · 2024-Sep-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
GnRH-a-based fertility-sparing treatment of atypical endometrial hyperplasia (AEH) and early endometrial carcinoma (EC) patients: a multicenter, open-label, randomized designed clinical trial protocol. PMID 39223633 · Trials · 2024-Sep-02 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Short Course Brachytherapy in Locally Advanced Cervical Cancer; Safety and Response Rate. PMID 39342591 · Asian Pac J Cancer Prev · 2024-Sep-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H B
影子组漏检补回 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Comparison between Trans-Arterial Chemoembolization Followed by Stereotactic Body Radiation Therapy and Trans-Arterial Chemoembolization Alone in BCLC Stage B Hepatocellular Carcinoma: A Pilot Study. PMID 39342585 · Asian Pac J Cancer Prev · 2024-Sep-01 The study is an oncology randomized trial with time-to-event endpoints, but it is ineligible due to: 1) No drug-containing intervention (the intervention is TACE±SBRT, which are locoregional procedures, not systemic drug therapy); 2) Phase evidence is insufficient (publication type includes 'Pilot Projects', suggesting it may be Phase II, not definitively Phase III/IIIb or II/III).
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Apixaban vs Aspirin in Patients With Cancer and Cryptogenic Stroke: A Post Hoc Analysis of the ARCADIA Randomized Clinical Trial. PMID 39133474 · JAMA Neurol · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Recurrence of Non-Small Cell Lung Cancer With Visceral Pleural Invasion: A Secondary Analysis of a Randomized Clinical Trial. PMID 39088196 · JAMA Oncol · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Preventive Effect of Neuromuscular Training on Chemotherapy-Induced Neuropathy: A Randomized Clinical Trial. PMID 38949824 · JAMA Intern Med · 2024-Sep-01 The record describes a randomized trial evaluating neuromuscular training to prevent chemotherapy-induced neuropathy in cancer patients receiving chemotherapy. While it is an oncology RCT with a drug-containing regimen and original results, it does not meet the core eligibility requirement of having a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) with Kaplan-Meier or HR analysis. The primary endpoint is the incidence of a toxicity (neuropathy), making this a safety/supportive care study, not an efficacy trial for a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Erratum to "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials". PMID 38848307 · Cancer · 2024-Sep-01 The record is a published erratum, not an original report of a trial's results. The title indicates it is an erratum to a previously published analysis focusing on surgical outcome as a prognostic factor in ovarian cancer, with no mention of a drug intervention or time-to-event efficacy endpoint in the abstract or metadata.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of drug-eluting bead with conventional transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus: a randomized clinical trial. PMID 38775550 · Int J Surg · 2024-Sep-01 The record meets most eligibility criteria (oncology, human, randomized, drug intervention, time-to-event endpoint, original result). However, it fails the 'phase3_or_definitive' criterion because the trial phase is not explicitly stated as Phase III, IIIb, or II/III in the provided metadata or abstract. The deterministic review also flags phase3 evidence as unclear.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial. PMID 38630903 · Cancer · 2024-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A Randomized Trial Comparing Quality of Life After Low-Dose Rate or High-Dose Rate Prostate Brachytherapy Boost With Pelvic External Beam Radiation Therapy. PMID 38493901 · Int J Radiat Oncol Biol Phys · 2024-Sep-01 Eligible RCT in oncology but excluded because the primary endpoint is not a time-to-event efficacy endpoint and the intervention is non-drug (radiation therapy comparison).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy of Mucosamin Spray as an Adjunct for Prevention of Oral Mucositis in Children under Chemotherapy: A Two-Center Randomized Clinical Trial. PMID 39371956 · J Dent (Shiraz) · 2024-Sep The study is an oncology RCT with a drug intervention and a time-to-event endpoint, but the publication metadata and abstract do not explicitly establish the trial phase as Phase III/IIIb or Phase II/III. It is described as a 'randomized clinical trial' without phase specification, so the phase criterion cannot be confirmed.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Translating efficacy of liver transplantation in liver-limited metastatic colorectal cancer into clinical practice: the TransMet trial. PMID 39341646 · ESMO Open · 2024-Sep The trial is randomized, human, oncological, and reports a time-to-event endpoint (OS). However, the primary intervention is liver transplantation (a surgical procedure), not a drug-containing intervention. The comparator is chemotherapy, but the trial is testing transplantation vs. chemotherapy, not a drug regimen. Therefore, it does not meet the drug-intervention criterion. Additionally, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided record.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single-arm, exploratory phase II trial. PMID 39324173 · Cancer Med · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The efficacy of gemcitabine and docetaxel chemotherapy for the treatment of relapsed and refractory osteosarcoma: A systematic review and pre-clinical study. PMID 39315544 · Cancer Med · 2024-Sep 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Long-Term Follow-Up of Patients with Advanced Colorectal Liver Metastasis: A Survival Analysis from the Randomized Controlled Multicenter Trial LIGRO. PMID 39310365 · Ann Surg Open · 2024-Sep The study is a randomized controlled trial (RCT) in oncology with a human population and a time-to-event efficacy endpoint (overall survival). However, it does not involve a drug-containing intervention (ALPPS and TSH are surgical procedures). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, and it cannot be assumed from the description.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Curcumin's effect in advanced and metastatic breast cancer patients treated with first or second-line docetaxel: A randomized trial. PMID 39286738 · Health Sci Rep · 2024-Sep The study is a Phase II randomized trial, which does not meet the criterion of being a Phase III/IIIb or Phase II/III definitive trial. All other criteria (oncology, human, randomized, drug intervention, original result, time-to-event endpoints) are met, but the phase criterion is not satisfied.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Inosine enhances the efficacy of immune-checkpoint inhibitors in advanced solid tumors: A randomized, controlled, Phase 2 study. PMID 39267574 · Cancer Med · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
mFOLFOX6 versus mFOLFOX6 + aflibercept as neoadjuvant treatment in MRI-defined T3-rectal cancer: a randomized phase-II-trial of the German Rectal Cancer Study Group (CAO/ARO/AIO 0214). PMID 39260162 · ESMO Open · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Clinical and molecular response to alpha1-oleate treatment in patients with bladder cancer. PMID 39254154 · Cancer Med · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation. PMID 39243304 · Clin Pharmacokinet · 2024-Sep The study is a randomized phase III trial with a drug intervention in oncology, but the primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR reporting. Instead, it reports categorical response rates (major molecular response) at fixed timepoints, which does not meet the time-to-event criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access? PMID 39232441 · ESMO Open · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Subcutaneous efgartigimod PH20 in generalized myasthenia gravis: A phase 3 randomized noninferiority study (ADAPT-SC) and interim analyses of a long-term open-label extension study (ADAPT-SC+). PMID 39227284 · Neurotherapeutics · 2024-Sep 未发现恶性肿瘤人群证据。
H L B
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
MRI Predicts Residual Disease and Outcomes in Watch-and-Wait Patients with Rectal Cancer. PMID 39225603 · Radiology · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
A multi-centre randomised controlled trial comparing megestrol acetate to levonorgestrel-intrauterine system in fertility sparing treatment of atypical endometrial hyperplasia. PMID 39215793 · J Assist Reprod Genet · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Induction avelumab followed by chemoimmunotherapy and maintenance versus chemotherapy alone as first-line therapy in cis-ineligible metastatic urothelial carcinoma (INDUCOMAIN): a randomized phase II study. PMID 39214051 · ESMO Open · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized trial of anetumab ravtansine and pembrolizumab compared to pembrolizumab for mesothelioma. PMID 39197359 · Lung Cancer · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
NANO-GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution. PMID 39184998 · Clin Transl Radiat Oncol · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Muscle matters: Prognostic implications of malnutrition and muscle health parameters in patients with cancer. A secondary analysis of a randomised trial. PMID 39181036 · Clin Nutr · 2024-Sep 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of CalliSpheres® drug-loaded microspheres combined with doxorubicin in hepatocellular carcinoma. PMID 39154241 · Scand J Gastroenterol · 2024-Sep The record is a randomized, human oncology trial with a drug intervention and time-to-event endpoints. However, the explicit trial phase (e.g., Phase III, Phase II/III) is not stated in the provided metadata or abstract. The 'publication_types' do not specify a definitive phase, and the 'deterministic_review' signal indicates phase evidence is unclear. Therefore, eligibility cannot be confirmed as true because the phase criterion is not explicitly established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Sunitinib for the treatment of patients with advanced pheochromocytomas or paragangliomas: The phase 2 non-randomized SUTNET clinical trial. PMID 39128186 · Eur J Cancer · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial. PMID 39116902 · Lancet Oncol · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Inflammatory response after prehospital high-dose glucocorticoid to patients resuscitated from out-of-hospital cardiac arrest: A sub-study of the STEROHCA trial. PMID 39094677 · Resuscitation · 2024-Sep 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -